- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2161–2184
of 6,882
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pain, Pancreatic Cancer
- Interventions
- Ultrasound guided celiac plexus neurolysis (CPN)
- Procedure
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Orlando, Florida
- Conditions
- Intimate Partner Violence (IPV)
- Interventions
- IDEA3 Sexual Assault Resistance Intervention, Consent workshop
- Behavioral
- Lead sponsor
- University of Maryland, College Park
- Other
- Eligibility
- 17 Years to 26 Years
- Enrollment
- 289 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Orlando, Florida • College Park, Maryland • Ann Arbor, Michigan
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, BI 1356 dose 3 once daily, BI 1356 dose 2 once daily, BI 1356 dose 1 once daily, Metformin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 34
- States / cities
- Chula Vista, California • La Jolla, California • Walnut Creek, California + 30 more
- Conditions
- Atrial Fibrillation
- Interventions
- Azimilide Dihydrochloride, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 69
- States / cities
- Mobile, Alabama • Tucson, Arizona • Burlingame, California + 63 more
- Conditions
- Diabetes Mellitus, Type 2, Hypertension
- Interventions
- Canagliflozin, Placebo
- Drug
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- FF/GW642444 Inhalation Powder, FF Inhalation Powder, GW642444 Inhalation Powder, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 47
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 42 more
- Conditions
- Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol
- Interventions
- Ad26.COV2.S, Placebo
- Biological · Other
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44,325 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 117
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 77 more
- Conditions
- Moral Injury, Anxiety, Depression, Burn-Out
- Interventions
- Clinician Questionnaire
- Other
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 483 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Dyslipidemia
- Interventions
- AZD8233 subcutaneous injection, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Chula Vista, California • Glendale, California • La Mesa, California + 4 more
- Conditions
- Psoriatic Arthritis
- Interventions
- Lutikizumab, Risankizumab, ABBV-701, ABBV-547
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 19
- States / cities
- Huntington Beach, California • Avon Park, Florida • Clearwater, Florida + 16 more
- Conditions
- Kidney Failure, Chronic
- Interventions
- JNJ-64565111
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Knoxville, Tennessee
- Conditions
- Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma
- Interventions
- GB-4362, enfortumab vedotin (EV), Pembrolizumab
- Drug
- Lead sponsor
- Generate Biomedicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Duarte, California • Irvine, California • Orlando, Florida + 7 more
- Conditions
- Depressive Disorder, Treatment-Resistant
- Interventions
- AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
- Conditions
- Congestive Heart Failure
- Interventions
- MyoCell, Hypothermosol
- Biological · Procedure
- Lead sponsor
- Bioheart, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 25 more
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Brenipatide, Placebo, Standard of Care
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Newport Beach, California • San Diego, California + 15 more
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
- Interventions
- Nivolumab, Ipilimumab, Lirilumab, Daratumumab, Pomalidomide, Dexamethasone
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 32
- States / cities
- Clovis, California • Los Angeles, California • Aurora, Colorado + 16 more
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, Escitalopram, JNJ-18038683
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 26
- States / cities
- Little Rock, Arkansas • Beverly Hills, California • Glendale, California + 23 more
- Conditions
- Major Depressive Disorder
- Interventions
- NMRA-335140, Placebo
- Drug
- Lead sponsor
- Neumora Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 57
- States / cities
- Encino, California • Garden Grove, California • Los Alamitos, California + 42 more
- Conditions
- Atopic Dermatitis, Eczema
- Interventions
- Bermekimab Monoclonal Antibody, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 17
- States / cities
- Huntington Beach, California • Coral Gables, Florida • Doral, Florida + 11 more
- Conditions
- Pharmacokinetic
- Interventions
- Cebranopadol 200 μg tablet
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Ametropia, Astigmatism
- Interventions
- Lehfilcon A toric contact lenses, Comfilcon A toric contact lenses, CLEAR CARE
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Oakland, California • San Francisco, California + 2 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Ambrisentan, Placebo, Sildenafil, Tadalafil
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- COPD, Smoking, Tobacco Use
- Interventions
- Cigarette, THS
- Other
- Lead sponsor
- Philip Morris Products S.A.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 46
- States / cities
- Clearwater, Florida • Coral Gables, Florida • Davie, Florida + 24 more